Q-omics provides the consensus-scored RGL4 profile across patient tissues and cancer cell-line models. RGL4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RGL4 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, RGL4 RNA expression shows 19,378 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where RGL4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RGL4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RGL4 survival associations across molecular data types. RGL4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RGL4 RNA expression–survival associations across cancer types. High RGL4 expression shows favorable associations in HNSC, BLCA, SKCM, BRCA, UCEC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RGL4 RNA expression.
This table summarizes RGL4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RGL4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RGL4 shows lower tumor expression in LUSC, BRCA and COAD and higher tumor expression in KIRC, KICH and CHOL. The KIRC box plot shows higher RGL4 RNA expression in tumor versus normal tissue (log2 FC = +0.443, t-test p < 0.001).
This table shows molecular features associated with RGL4 in patient tissues and cancer cell lines. In patient samples, RGL4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RGL4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
